chronic atrophic gastritis
Conditions
Interventions
Group A:Treatment of Weierkang
Group B:Treatment of Weierkang and folic acid
Group C:Treatment of Weifuchun
Sponsors
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 20 and 70 years old; 2. Gastroscopy was performed within one month, and 2 or more pathological biopsy sites were suggested (such as gastric antrum, stomach Angle), and had a complete gastroscopy and gastric mucosa biopsy data; 3. Outpatients was diagnosted as CAG, referring to consensus on chronic gastritis in China(Shanghai, 2012).
Exclusion criteria
Exclusion criteria: 1. Combined with malignant tumor,espencially esophageal cancer and gastric cancer; ulcer, barretts esophagus or other upper GI diseases; 2. Acid inhibitors (H2 antagonists or proton pump inhibitors) promote power medicine (mosapride or domperidone, etc.) or gastric mucosa protectant for pury (teprenone, sucralfate, gefarnate, glutamine, rebamipide, bismuth, etc.) were taken two weeks before this trial; 3. Serious comorbidities of heart, lung, liver, kidney or blood system; 4. Female patients preparing for a baby, pregnant or lactating; 5. Dropping out of this trials before the end of treatment, or can't cooperate with researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effective rate;The reverse rate; | — |
Countries
China
Contacts
Public ContactDai Ning
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Outcome results
None listed